Comparative Pharmacology
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus MINOCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus MINOCIN.
DEMECLOCYCLINE HYDROCHLORIDE vs MINOCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing aminoacyl-tRNA from attaching to the mRNA-ribosome complex.
Minocycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex.
150 mg orally every 6 hours or 300 mg orally every 12 hours. Maximum daily dose: 1200 mg.
100 mg orally or intravenously every 12 hours for 24 hours, then 100 mg every 12 hours; severe infections: 200 mg initially, then 100 mg every 12 hours.
None Documented
None Documented
10-17 hours; prolonged in renal impairment (up to 40–50 hours)
Terminal elimination half-life is 11–17 hours in patients with normal renal function; prolonged up to 18–69 hours in renal impairment.
Renal: 40-50% unchanged; fecal/biliary: 10-15%
Primarily renal (approximately 70% unchanged) and biliary/fecal (approximately 30%, with enterohepatic recycling).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic